Market By Drug Class, Distribution Channel, End-user, And Geography | Forecast 2019-2028
After a detailed analysis, Triton has concluded that the global immunosuppressant drugs market is expected to display an upward trend in terms of revenue. In addition, it is estimated to grow at a CAGR of 4.00% during the forecasting years 2019 to 2028. The market accounted for $9967.58 million in 2019 and is expected to reach $14185.67 million by 2028.
Immunosuppressant drugs
the ones which weaken the body's immune system. They are mostly used in organ transplantation
and autoimmune disorders. Immunosuppressant drugs based on class covered in the
report are corticosteroids, monoclonal antibodies, calcineurin inhibitors, mTOR
Inhibitors, and others.Â
Report scope can be customized per your requirements. Request For Customization
Corticosteroids are a class of drug which reduce body inflammation. These also reduce involvement in the immune system. They are medicines that mimic cortisol, a natural hormone. Monoclonal antibodies are immunoglobulins, made from a single clone of B-cells. Such antibodies, on a single antigen, identify specific epitopes or binding sites. These medicinal products are also commonly used in organ transplants. Calcineurin inhibitors belong to the drug class that inhibits the action of calcineurin. Calcineurin inhibitors (CNIs) are the cornerstone of immunosuppression for kidney transplantation. mTOR stands for mammalian target of rapamycin, and is widely used as immunosuppressant against autoimmune disorders. The other immunosuppressants include antiproliferative drug, interferons, and TNF binding proteins. These immunosuppressants are widely being used to treat autoimmune disorders.
The immunosuppressant drugs market report from Triton gives a detailed analysis of market definition, key insights, evolution & transition, Porter's five force analysis, market attractiveness index, and vendor scorecard.
Demand for drugs in organ transplantations and the rise in autoimmune diseases are the the two major factors that drive the market. Autoimmune disease is a condition wherein the immune system of the body erroneously attacks the healthy cells, organs and tissues, perceiving them as harmful to the body. At times such diseases can also be fatal. There is around 4% of the population that is affected by the disease. Immunosuppressant drugs suppress the effect of the immunity system of the body. Secondly, during organ transplantation, a body part of one individual (donor) is transplanted into another person (during organ failure or other reasons). Immunosuppressive drugs are widely used after organ transplantation procedures to combat the hyper-immune response of the recipient's immune system. Thereby, a rise in demand for organ transplantation procedures contributes to the market growth of the immunosuppressant drugs market.
The Asia-Pacific, Latin America, and the Middle East and Africa's emerging economies offer lucrative growth opportunities to expand the immunosuppressant drugs market, owing to the improving health services in these regions and the growing demand for better healthcare. Furthermore, the rise in the occurrence of various autoimmune disorders and the rise in work required to develop drugs to cure diseases are increasing the demand for immunosuppressants. In addition, the surge in healthcare reforms in developing countries is expected to offer remunerative opportunities for expanding the market.
Side-effects from immunosuppressant drugs and the lack of awareness about organ donation are the major restraints and challenges for the market. Organ transplantation forms around 52.77% of the market share, in 2019. Hence, its impact on the immunosuppressant drugs market is significant. Though the surge in demand for organ transplantation is on the rise, lack of awareness toward the same has been witnessed. Individuals are not aware of organ donation, and this lack of awareness can be witnessed in developed as well as developing countries.
Geographies covered for the immunosuppressant drugs market:
•          North America: United States and Canada
•          Europe: United Kingdom, Germany, France, Italy, Spain, Russia and Rest of Europe
•          Asia-Pacific: China, Japan, India, South Korea, ASEAN countries, Australia & New Zealand and Rest of Asia Pacific
•          Latin America: Brazil, Mexico and Rest of Latin America
•          The Middle East and Africa: United Arab Emirates, Turkey, Saudi Arabia, South Africa and Rest of the Middle East and Africa
The immunosuppressant drugs market, in this report, is segmented as follows:
•          Drug Class is sub-segmented into:
o         Corticosteroids
o         Monoclonal Antibodies
o         Calcineurin Inhibitors
o         mTOR Inhibitors
o         Others
•          Distribution Channel is sub-segmented into:
o         Hospital Pharmacies
o         Retail Pharmacies
o         Online Pharmacies
•          End-user is sub-segmented into:
o         Organ Transplantation
o         Autoimmune Disorders
o         Others
Major key players engaged in the immunosuppressant drugs market are Abbvie Inc, Allergan (acquired by Abbvie Inc), GlaxoSmithKline plc, Dr Reddys Laboratories Ltd, Astellas Pharma Inc, Cipla Ltd, Mylan NV, Bristol-Myers Squibb Company, Janssen Pharmaceuticals Inc (Johnson & Johnson Services Inc), Novartis AG, F Hoffmann-La Roche Ltd, Sanofi, Intas Pharmaceuticals Ltd (Accord Healthcare), Veloxis Pharmaceuticals Inc, and Pfizer Inc.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHTS
2.2.1.  ORGAN TRANSPLANTATION LEADS THE MARKET BY END-USER
2.2.2.  PHARMACEUTICAL INDUSTRY SHOWING GROWTH TRENDS
2.2.3.  IMPACT OF COVID 19 ON TRANSPLANT RECIPIENTS
2.3. EVOLUTION & TRANSITION OF IMMUNOSUPPRESSANT DRUGS
2.4. PORTER’S FIVE FORCE ANALYSIS
2.4.1.  THREAT OF NEW ENTRANTS
2.4.2.  THREAT OF SUBSTITUTE
2.4.3.  BARGAINING POWER OF SUPPLIERS
2.4.4.  BARGAINING POWER OF BUYERS
2.4.5.  THREAT OF COMPETITIVE RIVALRY
2.5. MARKET ATTRACTIVENESS INDEX
2.6. VENDOR SCORECARD
2.7. MARKET DRIVERS
2.7.1.  DEMAND FROM ORGAN TRANSPLANTATION
2.7.2.  RISE IN THE NUMBER OF AUTOIMMUNE DISORDERS
2.8. MARKET RESTRAINTS
2.8.1.  SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
2.9. MARKET OPPORTUNITIES
2.9.1.  DEMAND FROM EMERGING ECONOMIES
2.9.2.  EXPORTS OF DRUGS AND MEDICINE WORLDWIDE ON RISE
2.10. MARKET CHALLENGES
2.10.1. LACK OF AWARENESS ABOUT ORGAN DONATION
3. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET OUTLOOK – BY DRUG CLASS
3.1. CORTICOSTEROIDS
3.2. MONOCLONAL ANTIBODIES
3.3. CALCINEURIN INHIBITORS
3.4. MTOR INHIBITORS
3.5. OTHERS
4. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET OUTLOOK - BY DISTRIBUTION CHANNEL
4.1. HOSPITAL PHARMACIES
4.2. RETAIL PHARMACIES
4.3. ONLINE PHARMACIES
5. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET OUTLOOK - BY END-USER
5.1. ORGAN TRANSPLANTATION
5.2. AUTOIMMUNE DISORDERS
5.3. OTHERS
6. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET – REGIONAL OUTLOOK
6.1. NORTH AMERICA
6.1.1.  MARKET BY DRUG CLASS
6.1.2.  MARKET BY DISTRIBUTION CHANNEL
6.1.3.  MARKET BY END-USER
6.1.4.  COUNTRY ANALYSIS
6.1.4.1. UNITED STATES
6.1.4.2. CANADA
6.2. EUROPE
6.2.1.  MARKET BY DRUG CLASS
6.2.2.  MARKET BY DISTRIBUTION CHANNEL
6.2.3.  MARKET BY END-USER
6.2.4.  COUNTRY ANALYSIS
6.2.4.1. UNITED KINGDOM
6.2.4.2. GERMANY
6.2.4.3. FRANCE
6.2.4.4. SPAIN
6.2.4.5. ITALY
6.2.4.6. RUSSIA
6.2.4.7. REST OF EUROPE
6.3. ASIA-PACIFIC
6.3.1.  MARKET BY DRUG CLASS
6.3.2.  MARKET BY DISTRIBUTION CHANNEL
6.3.3.  MARKET BY END-USER
6.3.4.  COUNTRY ANALYSIS
6.3.4.1. CHINA
6.3.4.2. JAPAN
6.3.4.3. INDIA
6.3.4.4. SOUTH KOREA
6.3.4.5. ASEAN COUNTRIES
6.3.4.6. AUSTRALIA & NEW ZEALAND
6.3.4.7. REST OF ASIA-PACIFIC
6.4. LATIN AMERICA
6.4.1.  MARKET BY DRUG CLASS
6.4.2.  MARKET BY DISTRIBUTION CHANNEL
6.4.3.  MARKET BY END-USER
6.4.4.  COUNTRY ANALYSIS
6.4.4.1. BRAZIL
6.4.4.2. MEXICO
6.4.4.3. REST OF LATIN AMERICA
6.5. MIDDLE EAST AND AFRICA
6.5.1.  MARKET BY DRUG CLASS
6.5.2.  MARKET BY DISTRIBUTION CHANNEL
6.5.3.  MARKET BY END-USER
6.5.4.  COUNTRY ANALYSIS
6.5.4.1. UNITED ARAB EMIRATES
6.5.4.2. TURKEY
6.5.4.3. SAUDI ARABIA
6.5.4.4. SOUTH AFRICA
6.5.4.5. REST OF MIDDLE EAST & AFRICA
7. COMPETITIVE LANDSCAPE
7.1. ABBVIE INC
7.2. ALLERGAN (ACQUIRED BY ABBVIE INC)
7.3. ASTELLAS PHARMA INC
7.4. BRISTOL-MYERS SQUIBB COMPANY
7.5. CIPLA LTD
7.6. DR REDDYS LABORATORIES LTD
7.7. F HOFFMANN-LA ROCHE LTD
7.8. GLAXOSMITHKLINE PLC
7.9. INTAS PHARMACEUTICALS LTD (ACCORD HEALTHCARE)
7.10. JANSSEN PHARMACEUTICALS INC (JOHNSON & JOHNSON SERVICES INC)Â Â Â Â Â Â Â
7.11. MYLAN NV
7.12. NOVARTIS AG
7.13. PFIZER INC
7.14. SANOFI
7.15. VELOXIS PHARMACEUTICALS INC
8. METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE
8.2. SOURCES OF DATA
8.3. RESEARCH METHODOLOGY
TABLE 1: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY GEOGRAPHY, 2019-2028 (IN $ MILLION)
TABLE 2: MARKET ATTRACTIVENESS INDEX
TABLE 3: VENDOR SCORECARD
TABLE 4: SIDE-EFFECTS OF IMMUNOSUPPRESSANT DRUGS
TABLE 5: TOP 15 POSITIVE NET EXPORTS COUNTRIES AND NEGATIVE NET EXPORTS FOR DRUGS & MEDICINES COUNTRIES
TABLE 6: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2019-2028 (IN $ MILLION)
TABLE 7: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (IN $ MILLION)
TABLE 8: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, 2019-2028 (IN $ MILLION)
TABLE 9: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY GEOGRAPHY, 2019-2028 (IN $ MILLION)
TABLE 10: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 11: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2019-2028 (IN $ MILLION)
TABLE 12: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (IN $ MILLION)
TABLE 13: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, 2019-2028 (IN $ MILLION)
TABLE 14: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 15: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2019-2028 (IN $ MILLION)
TABLE 16: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (IN $ MILLION)
TABLE 17: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, 2019-2028 (IN $ MILLION)
TABLE 18: ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 19: ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2019-2028 (IN $ MILLION)
TABLE 20: ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (IN $ MILLION)
TABLE 21: ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, 2019-2028 (IN $ MILLION)
TABLE 22: LATIN AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 23: LATIN AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2019-2028 (IN $ MILLION)
TABLE 24: LATIN AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (IN $ MILLION)
TABLE 25: LATIN AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, 2019-2028 (IN $ MILLION)
TABLE 26: MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 27: MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2019-2028 (IN $ MILLION)
TABLE 28: MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (IN $ MILLION)
TABLE 29: MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, 2019-2028 (IN $ MILLION)
FIGURE 1: EVOLUTION & TRANSITION OF IMMUNOSUPPRESSANT DRUGS
FIGURE 2: PORTER’S FIVE FORCE ANALYSIS
FIGURE 3: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY CORTICOSTEROIDS, 2019-2028 (IN $ MILLION)
FIGURE 4: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY MONOCLONAL ANTIBODIES, 2019-2028 (IN $ MILLION)
FIGURE 5: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY CALCINEURIN INHIBITORS, 2019-2028 (IN $ MILLION)
FIGURE 6: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY MTOR INHIBITORS, 2019-2028 (IN $ MILLION)
FIGURE 7: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 8: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY HOSPITAL PHARMACIES, 2019-2028 (IN $ MILLION)
FIGURE 9: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY RETAIL PHARMACIES, 2019-2028 (IN $ MILLION)
FIGURE 10: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY ONLINE PHARMACIES, 2019-2028 (IN $ MILLION)
FIGURE 11: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY ORGAN TRANSPLANTATION, 2019-2028 (IN $ MILLION)
FIGURE 12: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY AUTOIMMUNE DISORDERS, 2019-2028 (IN $ MILLION)
FIGURE 13: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 14: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 15: UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 16: CANADA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 17: UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 18: GERMANY IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 19: FRANCE IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 20: SPAIN IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 21: ITALY IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 22: RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 23: REST OF EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 24: CHINA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 25: JAPAN IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 26: INDIA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 27: SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 28: ASEAN COUNTRIES IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 29: AUSTRALIA & NEW ZEALAND IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 30: REST OF ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 31: BRAZIL IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 32: MEXICO IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 33: REST OF LATIN AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 34: UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 35: TURKEY IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 36: SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 37: SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 38: REST OF MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)